Haisco Pharmaceutical Group Company Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
5,597
- Stock Symbol
-
002653
- Investments
-
10
- Share Price
-
$8.70
- (As of Friday Closing)
Haisco Pharmaceutical Group Company General Information
Description
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Contact Information
Website
www.haisco.comCorporate Office
- Number 43 Wenxiong Avenue
- Nedong District
- Shannan, Tibet 856000
- China
Corporate Office
- Number 43 Wenxiong Avenue
- Nedong District
- Shannan, Tibet 856000
- China
Haisco Pharmaceutical Group Company Stock Performance
As of 13-Nov-2026, Haisco Pharmaceutical Group Company’s stock price is $8.70. Its current market cap is $9.9B with 1.14B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.70 | $8.82 | $6.14 - $11.90 | $9.9B | 1.14B | 4.83M | $0.17 |
Haisco Pharmaceutical Group Company Financials Summary
As of 30-Sep-2026, Haisco Pharmaceutical Group Company has a trailing 12-month revenue of $879M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 10,624,396 | 8,345,089 | 5,207,125 | 3,728,061 |
| Revenue | 878,914 | 610,150 | 518,622 | 474,223 |
| EBITDA | 188,777 | 77,661 | 101,264 | 77,042 |
| Net Income | 189,125 | 36,096 | 55,112 | 41,713 |
| Total Assets | 1,344,738 | 1,001,973 | 931,280 | 938,533 |
| Total Debt | 338,421 | 282,931 | 261,694 | 254,846 |
Haisco Pharmaceutical Group Company Patents
Haisco Pharmaceutical Group Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228726-A1 | C-kit inhibitor and use thereof | Pending | 29-Apr-2025 | ||
| WO-2026228427-A1 | Pharmaceutical composition of complement factor b inhibitor and use thereof | Pending | 29-Apr-2025 | ||
| WO-2026219300-A1 | Large heterocyclic alk inhibitor and pharmaceutical use thereof | Pending | 17-Apr-2025 | ||
| WO-2026201022-A1 | Substituted heterocyclic compound and use thereof | Pending | 28-Mar-2025 | ||
| WO-2026200881-A1 | Gip receptor antagonist and pharmaceutical use thereof | Pending | 24-Mar-2025 |
Haisco Pharmaceutical Group Company Signals
Haisco Pharmaceutical Group Company Investments (10)
Haisco Pharmaceutical Group Company’s most recent deal was a Later Stage VC with Yixin Medical Devices. The deal was made on 21-Dec-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Yixin Medical Devices | 21-Dec-2023 | Later Stage VC | Therapeutic Devices | ||
| eXIthera Pharmaceuticals | 01-Apr-2019 | Later Stage VC | Drug Discovery | ||
| Pneuma Respiratory | 02-Dec-2018 | Early Stage VC | Therapeutic Devices | ||
| Laminate Medical Technologies | 07-Feb-2017 | Later Stage VC | Therapeutic Devices | ||
| Regentis Biomaterials | 05-Feb-2016 | Later Stage VC | Therapeutic Devices |
Haisco Pharmaceutical Group Company ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Haisco Pharmaceutical Group Company Exits (5)
Haisco Pharmaceutical Group Company’s most recent exit was on 01-Apr-2019 from eXIthera Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| eXIthera Pharmaceuticals | 01-Apr-2019 | Completed |
|
||
| Regentis Biomaterials | 05-Feb-2016 | Completed |
|
||
| Hinova Pharmaceuticals | 01-Jan-2016 | Completed |
|
||
| Endospan | 21-Oct-2015 | Completed |
|
||
| Medical Surgery Technologies | 30-Jun-2015 | Later Stage VC | Completed |
|
Haisco Pharmaceutical Group Company FAQs
-
When was Haisco Pharmaceutical Group Company founded?
Haisco Pharmaceutical Group Company was founded in 2000.
-
Where is Haisco Pharmaceutical Group Company headquartered?
Haisco Pharmaceutical Group Company is headquartered in Shannan, China.
-
What is the size of Haisco Pharmaceutical Group Company?
Haisco Pharmaceutical Group Company has 5,597 total employees.
-
What industry is Haisco Pharmaceutical Group Company in?
Haisco Pharmaceutical Group Company’s primary industry is Medical Supplies.
-
Is Haisco Pharmaceutical Group Company a private or public company?
Haisco Pharmaceutical Group Company is a Public company.
-
What is Haisco Pharmaceutical Group Company’s stock symbol?
The ticker symbol for Haisco Pharmaceutical Group Company is 002653.
-
What is the current stock price of Haisco Pharmaceutical Group Company?
As of 13-Nov-2026 the stock price of Haisco Pharmaceutical Group Company is $8.70.
-
What is the current market cap of Haisco Pharmaceutical Group Company?
The current market capitalization of Haisco Pharmaceutical Group Company is $9.9B.
-
What is Haisco Pharmaceutical Group Company’s current revenue?
The trailing twelve month revenue for Haisco Pharmaceutical Group Company is $879M.
-
What is Haisco Pharmaceutical Group Company’s annual earnings per share (EPS)?
Haisco Pharmaceutical Group Company’s EPS for 12 months was $0.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process